SRX GLOBAL INC 424B Filings

SRX Global Inc. filed a prospectus supplement covering the resale, from time to time, of up to 41,781,566 shares of common stock by Keystone Capital Partners under a Common Share Purchase Agreement. The company will not receive proceeds from Keystone’s resales, though it may receive cash when it elects to sell shares to Keystone; the registered amount reflects the completed 1-for-60 reverse stock split effective July 6, 2026.

SRX Global recently closed its acquisition of EMJ Crypto Technologies and related entities, issuing an aggregate of 268,346,659 common shares, 117,268,196 exchangeable shares and 44,368,530 pre-funded warrants, and changed its name from SRx Health Solutions, Inc. to SRX Global Inc. Following the July 6 share consolidation, the company reports preliminary June 30, 2026 figures of approximately $40 million in cash, more than $15 million in short‑term investments, estimated net asset value of about $60 million or $3.07 per share, and approximately 19,517,834 shares outstanding, with no debt.

The board approved a one-time cash dividend of $0.05 per share (about $1 million in total) and authorized a share repurchase program for up to 10 million shares, or up to 50% of shares outstanding, with up to $20 million allocated. Management highlights EMJX’s AI‑driven, paper‑traded strategy, which it reports returned 24.8% from February 11 to July 10, 2026 versus Bitcoin at -4.2%, and states an intention to deploy real capital into this framework. After the reverse split, NYSE American confirmed SRX Global is back in compliance with its continued listing standards.

SRx Health Solutions, Inc. registered up to 2,506,893,959 shares of Common Stock for resale by Keystone Capital Partners, LLC. This prospectus supplement to the Prospectus covers resale of those shares by the Selling Stockholder and attaches related Form 8-Ks filed March 18, April 17 and April 22, 2026. The Company states it will not receive proceeds from resale transactions by Keystone, though it may receive proceeds if it itself sells shares to Keystone under the ELOC Purchase Agreement. The supplement also describes a March 16, 2026 private placement: issuance of 5,660 Series B Preferred Shares and 22,237,666 Warrants for aggregate proceeds of approximately $4.528 million. Warrant exercise and preferred conversion mechanics, anti-dilution protections, a 4.99% beneficial ownership limit and extensive Triggering Event provisions are included.

SRx Health Solutions, Inc. updates a prospectus supplement registering the resale by selling stockholders of up to 187,544,974 shares of Common Stock for resale by the named selling stockholders, subject to beneficial ownership and exchange limitations. The resale pool aggregates multiple classes of underlying securities, including warrants, convertible preferred stock conversion rights, exchangeable Canadian shares, private placement shares, service provider shares and shares issued in a share exchange. The Company notes a closing market price of $0.1300 per share on June 4, 2026. The prospectus supplement incorporates recent 8-Ks dated March 18, 2026, April 17, 2026, and April 22, 2026 and discloses a separate March 16, 2026 private placement that issued 5,660 Series B Preferred Shares and 22,237,666 warrants for approximately $4.528 million.

SRx Health Solutions discloses a proposed all-stock acquisition to buy EMJ Crypto Technologies, CCC Crypto Corp. and related intellectual property for an aggregate purchase price of approximately $55 million under a Share Exchange and Asset Transfer Agreement dated December 16, 2025 (amended March 11, 2026). The prospectus covers up to 550,000,000 SRXH common shares issuable as consideration, including exchangeable shares and pre-funded warrants. The Board recommended the Transaction and certain stockholders holding 14,180,156 shares (representing 51.15%) delivered written consents approving the proposals; no proxy solicitation will occur. The parties expect the closing in Q2 2026, subject to customary conditions and NYSE American and other regulatory approvals.

SRx Health Solutions, Inc. files a prospectus supplement registering the resale of up to 187,552,665 shares of Common Stock by existing selling stockholders. The resale stock consists of multiple tranches including warrants, convertible-preferred-related shares, exchangeable Canadian shares, private placement shares, service‑provider shares and shares issued in a share exchange, and is offered by selling stockholders subject to applicable lock-up, vesting, beneficial ownership and stock exchange limitations described herein. The supplement attaches a Form 8-K describing a limited waiver and consent permitting a new preferred‑stock offering and related waivers among existing investors.

SRx Health Solutions, Inc. registers up to 2,506,893,959 shares of common stock for resale by Keystone Capital Partners, LLC.

The prospectus supplement states these shares are outstanding or issuable under a Common Share Purchase Agreement and that the Company will not receive proceeds from any resales by the selling stockholder; the Company may, at its discretion, sell shares to Keystone under the Purchase Agreement.

SRx Health Solutions, Inc. files a prospectus supplement registering up to 187,552,665 shares of common stock for resale by named selling stockholders, consisting of PIPE‑related warrants and conversions, exchangeable shares, private placement shares, service provider shares and shares issued in a share exchange.

The resale is by the Selling Stockholders or their permitted transferees from time to time, subject to lock-up, vesting, beneficial‑ownership and exchange limitations described in the prospectus supplement. The supplement incorporates the Company’s Form 10‑Q for the quarter ended December 31, 2025, which discloses continuing operations (consumer pet products), discontinued SRx Canada operations, a net loss of $8.614 million for the quarter, and digital assets of $7.996 million at fair value as of December 31, 2025.

SRx Health Solutions, Inc. files a prospectus supplement registering up to 2,506,893,959 shares of common stock for resale by Keystone Capital Partners, LLC, including shares outstanding or issuable under a Common Share Purchase Agreement.

The prospectus states the company will not receive proceeds from any resales by the selling stockholder; the company may, at its discretion, sell shares to Keystone under the ELOC Purchase Agreement and would receive proceeds if it does so. The filing incorporates the Company’s Form 10-Q for the quarter ended December 31, 2025 and discloses 298,207,684 shares outstanding as of February 11, 2026.

SRx Health Solutions, Inc. files a prospectus supplement to register up to 2,506,893,959 shares of common stock for resale by Keystone Capital Partners, LLC. The registration covers resale only; the Company will not receive proceeds from sales by the Selling Stockholder, though it may receive proceeds if it sells shares to Keystone under the ELOC Purchase Agreement.

The supplement also attaches an 8-K disclosing that the NYSE American issued a public warning for failures to comply with Sections 301 and 713 after the Company issued approximately 7.5 million shares upon conversion of Series A preferred stock; all Preferred Shares have been converted or redeemed.

SRx Health Solutions, Inc. registered for resale up to 187,552,665 shares of common stock under a prospectus supplement dated February 26, 2026. The resale pool includes shares issuable on conversion or exercise from prior PIPE financings, exchangeable Canadian shares, private placement shares, service provider shares, and shares issued in a share exchange.

The company also reported receipt of a public Warning Letter from NYSE Regulation dated February 18, 2026, citing failures to obtain exchange listing approval and adequate shareholder approval related to approximately 7.5 million common shares issued upon conversion of Series A Convertible Preferred Stock. As of the report, all Preferred Shares have been converted or redeemed and no Preferred Shares remain outstanding.

SRx Health Solutions, Inc. has filed a prospectus supplement covering the resale by selling stockholders of up to 187,552,665 shares of common stock. These shares include stock underlying July and October PIPE securities, exchangeable shares, prior private placements, service provider awards, and a share exchange transaction.

Separately, the company redeemed all outstanding Series A preferred stock for an aggregate redemption price of approximately $21,772,500125,000,000 shares of common stock on an as-converted basis, which the company states is intended to improve balance sheet flexibility for potential M&A or returns of capital.

SRx Health Solutions, Inc. is registering up to 2,506,893,959 shares of common stock for resale by Keystone Capital Partners under a common share purchase agreement. The company will not receive proceeds from Keystone’s resales, but can receive cash when it sells shares to Keystone under the equity line.

Separately, SRx Health redeemed 17,418 shares of its Series A Convertible Preferred Stock for an aggregate redemption price of approximately $21,772,500, representing about 125,000,000 common shares on an as-converted basis. The preferred redemption and related common share cancellation are described as improving balance sheet flexibility for potential future M&A or returns of capital.

SRx Health Solutions, Inc. filed a prospectus supplement covering the resale of up to 187,552,665 shares of common stock held by selling stockholders. These shares come from prior PIPE financings in July and October 2025, exchangeable shares issued in connection with SRx Health Solutions (Canada), a private placement, service provider share issuances, and shares issued under a share exchange with Halo Spin-Out SPV Inc.

The supplement includes a Current Report on Form 8-K describing stockholder written consents dated December 17, 2025. Stockholders approved a future name and ticker change to EMJX, a potential issuance of at least 20% of outstanding common stock for a transaction to acquire EMJ Crypto Technologies Inc., CCC Crypto Corp. and related AI-based intellectual property, an increase in the 2019 Incentive Award Plan share pool, the election of four directors, advisory approval of executive compensation, and ratification of Davidson and Company LLP as auditor. These actions were approved by holders of 45.42% of the company’s voting power as of the December 12, 2025 record date.

SRx Health Solutions, Inc. is registering up to 187,544,974 shares of common stock for resale by existing holders, including shares issuable from PIPE financings, exchangeable shares, private placements, service provider grants and a prior share exchange. The company will not receive proceeds from these resales, which could put pressure on the share price because the registered amount represents a meaningful portion of its public float.

The prospectus describes significant financing arrangements, including July and October PIPE deals, an equity line of credit that may allow sales of up to $1.0 billion of common shares, and a $20.0 million convertible note tied to that facility. It also highlights serious risks: the auditors have raised substantial doubt about the company’s ability to continue as a going concern, the Canadian subsidiary SRx Canada is in CCAA restructuring with asset sales under court supervision, and the Halo pet business has recurring losses and intense competitive and operational pressures.

SRx Health Solutions, Inc. filed a prospectus supplement covering the resale of up to 2,506,893,959 shares of common stock by Keystone Capital Partners, LLC. These shares are outstanding or issuable under a common share purchase agreement, and any sale by Keystone will not send cash to the company, although SRx would receive funds when it sells shares to Keystone under that agreement.

Separately, stockholders holding 45.42% of voting power approved several actions by written consent as of December 17, 2025. These include a planned name change to EMJX, Inc. and ticker change to EMJX conditioned on closing a proposed transaction to acquire EMJ Crypto Technologies Inc., CCC Crypto Corp., and related artificial intelligence trading intellectual property. Stockholders also approved potential issuance of common stock equal to 20% or more of current outstanding shares in connection with this transaction, an increase in the 2019 Incentive Award Plan pool, election of four directors to terms through the 2026 annual meeting, advisory approval of executive compensation, and ratification of Davidson and Company LLP as independent auditor for 2025.

SRx Health Solutions, Inc. is registering up to 2,506,893,959 shares of common stock for resale by Keystone Capital Partners under a Common Share Purchase Agreement. These shares are outstanding or issuable to Keystone, which may sell them over time, and SRx will only receive cash when it sells shares to Keystone, not from Keystone’s subsequent resales.

The company also entered into a Share Exchange and Asset Transfer Agreement to acquire EMJ Crypto Technologies Inc., CCC Crypto Corp., and certain artificial-intelligence-based IP assets in an all‑stock transaction valued at approximately $55 million. Closing requires stockholder approval, NYSE American listing of the new shares, effectiveness of a Form S‑4 registration statement, accurate representations by all parties, and other customary conditions, and the deal may be terminated if not completed by June 30, 2026, with certain termination expense reimbursements capped at $300,000 each way.